Articles

Poll

Podcasts

Slideshows

Videos

Hepatology

Strnad emphasizes the promise offered by RNA therapeutics in liver disease and what potential fazirsiran may hold for AATD liver disease in a broad spectrum of patients.

Fazirsiran and the Future of RNA Therapy in AATD Liver Disease, With Pavel Strnad, MD

Clark reviews findings from a 3-year longitudinal study comparing VCTE to liver biopsy for staging F2/F3 fibrosis in patients with AATD liver disease.

VCTE’s Potential for Monitoring AATD Liver Disease, With Virginia Clark, MD

Read about hepatic FDA news, the voluntary withdrawal of obeticholic acid for PBC, new trial data for a potential AATD drug, and more.

5 Hepatology Headlines You Missed in September 2025

WVE-006 drove production of M-AAT, which is protective of lung function, and reduced mutant Z-AAT, a cause of liver disease.

RestorAATion-2: WVE-006 Achieves Durable Serum AAT Protein Production in AATD

Stoller describes the potential of a novel AI model to help address AATD underrecognition, citing findings from his research on its performance in a Cleveland Clinic cohort.

Leveraging AI to Overcome Underrecognition of AATD, with James Stoller, MD

Meta-analysis results showed patients with ZZ AATD had a greater risk of liver disease and liver cancer than patients in comparator cohorts.

ZZ Genotype Linked to More Severe AATD-Related Liver Disease

Clark reviews open-label extension data from the phase 2b SEQUOIA study of fazirsiran for AATD liver disease.

Virginia Clark, MD: Understanding Fazirsiran’s Potential in AATD Liver Disease

Fromme describes the importance of risk stratification in AATD and explains the potential utility of noninvasive fibrosis measures for predicting outcomes.

Malin Fromme, MD: Lung, Liver Risk Stratification in Alpha-1 Antitrypsin Deficiency

Strnad reviews findings from a proteomic analysis about AATD-associated liver disease and how they may aid future disease monitoring and drug development.

Pavel Strnad, MD: The Underlying Molecular Mechanisms of PI*ZZ AATD Liver Disease

Teckman explains the value of a new predictive algorithm model for determining future risk of portal hypertension, cirrhosis, and liver transplant in AATD.

Alpha-1 antitrypsin deficiency